Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gensia plans to cash out Aramed

Gensia plans to cash out Aramed

Gensia Inc. ended the suspense for its Aramed Inc. shareholders, announcing on Friday an agreement under which GNSA will acquire ARAM for about $37.4 million, far less than the $159 million GNSA would have owed at the end of this year under the companies' 1991 agreement.

On a per share basis, ARAM shareholders will

Read the full 594 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE